No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease

No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: لاله فرزین , سمیه اصغری , مریم رف رف , محمد اصغری جعفرآبادی , مسعود شیرمحمدی

کلمات کلیدی: resveratrol,supplementation,atherogenic indexes,nonalcoholic fatty liver disease

نشریه: 55233 , 1 , 1 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله مریم رف رف
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات علوم تغذیه
کد مقاله 66234
عنوان فارسی مقاله No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease
عنوان لاتین مقاله No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease
ناشر 5
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح دو – PubMed
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Abstract: Introduction: Cardiovascular disease (CVD) accounts as a major cause of mortality among patients with nonalcoholic fatty liver disease (NAFLD). Resveratrol, a natural polyphenol compound, is known for its antioxidant and antiatherogenic properties and is purported to be beneficial in decreasing CVD risk factors in NAFLD patients. Objectives: This study aimed to investigate the effects of resveratrol on atherogenic risk factors in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed on 50 patients with NAFLD aged 20-60 years. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (n=25) or placebo (n=25) for 12 wk. Serum liver enzymes, lipid profile and atherogenic indices, blood pressure and anthropometric values were assessed pre and post-treatment. Results: Resveratrol supplementation reduced body weight (from 88.75±11.41 to 87.54±11.18 kg, P=0.005) and BMI (from 31.00±3.16 to 30.60±3.26 kg/m², P=0.01) significantly compared to the placebo group. A significant reduction in waist circumference was observed within resveratrol group (from 102.70±7.68 to 101.39±7.62 cm, P=0.02). There were no significant changes in lipid profile (ox-LDL, ApoA1 and ApoB), serum atherogenic indices (LDL-C/HDL-C, ApoB/ApoA1, ox-LDL/ApoB, LDL-C/ox-LDL and AIP), liver enzymes (AST, ALT, ALP and GGT), hip circumference, waist-to-hip ratio and blood pressure in either group (P>0.05 for all).Conclusion: These findings indicated that resveratrol supplementation in dose and duration used in this study did not affect most of the CVD risk factors in NAFLD patients. Further studies are warranted to explain more effects of resveratrol on CVD complications of NAFLD. Registration ID in IRCT: IRCT201511233664N16

نویسندگان
hide/show

نویسنده نفر چندم مقاله
لاله فرزیناول
سمیه اصغریدوم
مریم رف رفسوم
محمد اصغری جعفرآبادیچهارم
مسعود شیرمحمدیپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
farzin.print.pdf1397/12/26427970دانلود